Phase 1 study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies

BACKGROUND: The novel bispecific ligand-directed toxin (BLT) DT2219 consists of a recombinant fusion between the catalytic and translocation enhancing domain of diphtheria toxin (DT) and bispecific single chain variable fragments (scFV) of antibodies targeting human CD19 and CD22. We conducted a pha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Bachanova, Veronika, Frankel, Arthur E., Cao, Qing, Lewis, Dixie, Grzywacz, Bartosz, Verneris, Michael R., Ustun, Celalettin, Lazaryan, Aleksandr, McClune, Brian, Warlick, Erica D., Kantarjian, Hagop, Weisdorf, Daniel J., Miller, Jeffrey S., Vallera, Daniel A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4360883/
https://ncbi.nlm.nih.gov/pubmed/25770294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2877
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados